ARTICLE | Company News
biOasis, Vaccinex deal
September 26, 2016 7:00 AM UTC
biOasis granted Vaccinex commercialization rights to use biOasis’ Transcend delivery technology with Vaccinex’s anti- semaphorin 4D (SEMA4D) antibodies. biOasis is eligible for up to $20 million in u...